Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522888-15-00

Enrollment

Registered

2026-05-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

None listed

Source: EU CTIS · Data processed: May 6, 2026